Market closed
Humacyte/$HUMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Humacyte
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
Ticker
$HUMA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
219
Website
Humacyte Metrics
BasicAdvanced
$240M
-
-$1.26
1.36
-
Price and volume
Market cap
$240M
Beta
1.36
52-week high
$9.97
52-week low
$1.15
Average daily volume
5M
Financial strength
Current ratio
2.398
Quick ratio
2.252
Long term debt to equity
-146.147
Total debt to equity
-153.817
Interest coverage (TTM)
-12.33%
Management effectiveness
Return on assets (TTM)
-53.74%
Return on equity (TTM)
760.17%
Valuation
Price to book
-3.74
Price to tangible book (TTM)
-3.74
Price to free cash flow (TTM)
-1.842
Growth
Earnings per share change (TTM)
17.17%
3-year earnings per share growth (CAGR)
23.74%
What the Analysts think about Humacyte
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Humacyte stock.
Humacyte Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Humacyte Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Humacyte News
AllArticlesVideos
Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript
Seeking Alpha·3 weeks ago
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
GlobeNewsWire·3 weeks ago
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Humacyte stock?
Humacyte (HUMA) has a market cap of $240M as of April 18, 2025.
What is the P/E ratio for Humacyte stock?
The price to earnings (P/E) ratio for Humacyte (HUMA) stock is 0 as of April 18, 2025.
Does Humacyte stock pay dividends?
No, Humacyte (HUMA) stock does not pay dividends to its shareholders as of April 18, 2025.
When is the next Humacyte dividend payment date?
Humacyte (HUMA) stock does not pay dividends to its shareholders.
What is the beta indicator for Humacyte?
Humacyte (HUMA) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.